728 related articles for article (PubMed ID: 33937058)
1. Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
Borisov N; Sergeeva A; Suntsova M; Raevskiy M; Gaifullin N; Mendeleeva L; Gudkov A; Nareiko M; Garazha A; Tkachev V; Li X; Sorokin M; Surin V; Buzdin A
Front Oncol; 2021; 11():652063. PubMed ID: 33937058
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.
Chen L; Yi K; Lan H; Zhang Y; Jin S; Mou X; Xian H; Fu W; Li R
Ann Transl Med; 2022 Jun; 10(12):674. PubMed ID: 35845500
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma.
Toor SH; Satti TM; Iftikhar R; Mahmood SK; Shamshad GU; Rehman JU
J Coll Physicians Surg Pak; 2020 May; 30(5):527-531. PubMed ID: 32580853
[TBL] [Abstract][Full Text] [Related]
7. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
[TBL] [Abstract][Full Text] [Related]
8. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
Huang BT; Tan Y; Zhao WH; Zeng QC; Li BS; Chen RL
J Cancer Res Clin Oncol; 2014 Feb; 140(2):303-9. PubMed ID: 24337419
[TBL] [Abstract][Full Text] [Related]
9. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
Major A; Jakubowiak A; Derman B
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1000-e1008. PubMed ID: 35922273
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
[TBL] [Abstract][Full Text] [Related]
13. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Uttervall K; Borg Bruchfeld J; Gran C; Wålinder G; Månsson R; Lund J; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2019 Sep; 103(3):247-254. PubMed ID: 31231833
[TBL] [Abstract][Full Text] [Related]
14. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation.
Crusoe EQ; Higashi F; Martinez G; Bittencourt R; Pinto Neto JV; Sousa L; Santucci R; Magalhães RJP; Colli G; Nunes RFM; Ribeiro G; Nicacio J; Zanella KR; Kutner JM; Magalhaes A; Leao D; Hallack Neto AE; Braga W; Souza EG; Guimaraes AJAM; Durigon GS; Laks D; Maiolino A; Hungria VTM;
Hematol Transfus Cell Ther; 2020; 42(2):118-124. PubMed ID: 31537476
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients.
Ciftciler R; Goker H; Buyukasik Y; Sayınalp N; Haznedaroglu IC; Aksu S; Ozcebe O; Demiroglu H
Hematol Rep; 2020 May; 12(1):8267. PubMed ID: 32399162
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V; Palladini G; Minnema MC; Jaccard A; Lee HC; Gibbs S; Mollee P; Venner C; Lu J; Schönland S; Gatt M; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Chauveau D; Gries KS; Fastenau J; Tran NP; Qin X; Vasey SY; Weiss BM; Vermeulen J; Ho KF; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD
Am J Hematol; 2022 Jun; 97(6):719-730. PubMed ID: 35293006
[TBL] [Abstract][Full Text] [Related]
18. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
Wang SY; Holzhey T; Heyn S; Zehrfeld T; Fricke S; Hoffmann FA; Becker C; Braunert L; Edelmann T; Paulenz I; Hitzschke M; Flade F; Schwarzer A; Fenchel K; Franke GN; Vucinic V; Jentzsch M; Schwind S; Hell S; Backhaus D; Lange T; Niederwieser D; Scholz M; Platzbecker U; Pönisch W
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3739-3752. PubMed ID: 35987926
[TBL] [Abstract][Full Text] [Related]
19. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
